

# Factsheet | The Biosimilar Medicines Group



## About the Biosimilar Medicines Group


The **Biosimilar Medicines Group**, a sector group of **Medicines for Europe**, represents the leading companies in the biosimilar medicines space. The Biosimilar Medicines Group members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

**Medicines for Europe** represents the European generic, biosimilar and value added medicines industries, which provide high-quality cost-competitive medicines to millions of Europeans. The vision of **Medicines for Europe** is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: **patients, quality, value, sustainability** and **partnership**.

The Biosimilar Medicines Group is open to **Medicines for Europe** and non-**Medicines for Europe** members.

For more information please follow us at [www.medicinesforeurope.com](http://www.medicinesforeurope.com) and on Twitter [@biosimilarsEU](https://twitter.com/biosimilarsEU)

## Biosimilar Medicines: Key Facts



## Biosimilar Medicines Group Membership

### COMPANIES

Accord Healthcare  
Apobiologix  
Boehringer Ingelheim  
CinnaGen  
Cinfa Biotech  
Egis  
Formycon  
Fresenius Kabi

Gedeon Richter  
Mylan  
Polpharma  
Samsung Bioepis  
Sandoz  
Stada  
Teva

### NATIONAL ASSOCIATIONS

APOGEN (Portugal)  
AssoGenerici (Italy)  
BOGIN (Netherlands)  
BGMA (United Kingdom)  
CAFF (Czech Republic)  
FeBelGen (Belgium)  
FGA (Finland)  
FGL (Sweden)  
GEMME (France)

GENAS (Slovakia)  
IEIS (Turkey)  
IGL (Denmark)  
Italian Biosimilars Group (a group of  
Assogenerici) (Italy)  
Probiosimilars (a group of ProGenerika)  
(Germany)  
Intergenerika (Switzerland)



Follow us on



@biosimilarsEU